S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
This Small-Cap Healthcare Name Is Outperforming Its Index
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
What Cintas Can Teach Investors About This Bear Market?
Wall Street drops back to lowest since 2020 as fear returns
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
NATO believes Baltic Sea gas leaks were sabotage
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
This Small-Cap Healthcare Name Is Outperforming Its Index
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
What Cintas Can Teach Investors About This Bear Market?
Wall Street drops back to lowest since 2020 as fear returns
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
NATO believes Baltic Sea gas leaks were sabotage
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
This Small-Cap Healthcare Name Is Outperforming Its Index
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
What Cintas Can Teach Investors About This Bear Market?
Wall Street drops back to lowest since 2020 as fear returns
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
NATO believes Baltic Sea gas leaks were sabotage
UK's Truss defends economic plan that sent pound tumbling
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
This Small-Cap Healthcare Name Is Outperforming Its Index
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
What Cintas Can Teach Investors About This Bear Market?
Wall Street drops back to lowest since 2020 as fear returns
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
NATO believes Baltic Sea gas leaks were sabotage
UK's Truss defends economic plan that sent pound tumbling

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

$3.50
-0.07 (-1.96%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.44
$3.62
50-Day Range
$3.13
$4.25
52-Week Range
$1.67
$4.74
Volume
284,181 shs
Average Volume
395,363 shs
Market Capitalization
$296.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
214.3% Upside
$11.00 Price Target
Short Interest
Healthy
2.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
1.71mentions of CymaBay Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.21) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

167th out of 1,097 stocks

Pharmaceutical Preparations Industry

63rd out of 548 stocks

CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

CymaBay to Host Virtual Analyst Day Next Week
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
CymaBay Therapeutics Misses Q2 EPS by 2c
Did Biden Bet the Future of America on the "Lithium Triangle"?
FREE investor's report details the plan to cut more ties with China and how it could create the next boom for early investors. But you must act fast.
CymaBay Therapeutics: Q1 Earnings Insights
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings
8/11/2022
Today
9/30/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+214.3%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-90,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Miscellaneous

Free Float
79,936,000
Market Cap
$296.38 million
Optionable
Optionable
Beta
0.62

Key Executives

  • Mr. Sujal A. Shah (Age 49)
    Pres, CEO & Director
    Comp: $873.87k
  • Dr. Dennis D. Kim M.B.A. (Age 52)
    M.D., MBA, Chief Medical Officer
    Comp: $406.11k
  • Mr. Lewis J. Stuart B.A. (Age 63)
    BA, M.B.A., MBA, Chief Commercial Officer
    Comp: $378.79k
  • Mr. Daniel Menold (Age 52)
    VP of Fin.
  • Dr. Charles A. McWherter Ph.D. (Age 67)
    Sr. VP & Chief Scientific Officer
  • Mr. Paul T. Quinlan (Age 59)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ken Boehm
    Sr. VP of HR
  • Mr. Patrick J. O'Mara (Age 61)
    Sr. VP of Bus. Devel.
  • Dr. Robert L. Martin (Age 60)
    Sr. VP of Manufacturing & Nonclinical Devel.
  • Ms. Klara A. Dickinson-Eason (Age 54)
    Chief Regulatory & Quality Assurance Officer













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued 12 month price objectives for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $8.00 to $14.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 214.3% from the stock's current price.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2022?

CymaBay Therapeutics' stock was trading at $3.38 at the beginning of the year. Since then, CBAY shares have increased by 3.6% and is now trading at $3.50.
View the best growth stocks for 2022 here
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings data on Thursday, August, 11th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. During the same quarter in the prior year, the business earned ($0.34) earnings per share.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $3.50.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $296.37 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.